An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Public ClinicalTrials.gov record NCT02003144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
Study identification
- NCT ID
- NCT02003144
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 119 participants
Conditions and interventions
Interventions
- eculizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2015
- Primary completion
- Jul 11, 2021
- Completion
- Jul 11, 2021
- Last update posted
- Aug 22, 2022
2015 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| The Research Center of Southern California | Oceanside | California | 92056 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| University of Miami McKnight Brain Institute | Miami | Florida | 33136 | — |
| Neurological Services of Orlando | Orlando | Florida | 32806 | — |
| Allied Physicians Inc. of Fort Wayne | Fort Wayne | Indiana | 46805 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Baptist Health Lexington | Nicholasville | Kentucky | 40503 | — |
| Johns Hopkins University Medical Center | Baltimore | Maryland | 21287 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Multiple Sclerosis Comprehensive Care Center NYU Langone Medical Center | New York | New York | 10016 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Ohio Health Reserach Institute | Columbus | Ohio | 43214 | — |
| University of Pennsylvania School of Medicine | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | — |
| Multiple Sclerosis Treatment Center of Dallas | Dallas | Texas | 75246 | — |
| The University of Texas Health Science | San Antonio | Texas | 78229 | — |
| University of Utah | Salt Lake City | Utah | 84108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02003144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02003144 live on ClinicalTrials.gov.